{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:24:26Z","timestamp":1790497466504,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.omto.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T12:48:50Z","timestamp":1659703730000},"page":"347-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies"],"prefix":"10.1016","volume":"26","author":[{"given":"Lindsey A.","family":"McAlarnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunila","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-3460","authenticated-orcid":false,"given":"Pradeep","family":"Chaluvally-Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2022.08.005_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.omto.2022.08.005_bib3","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1001\/jama.1983.03340220040030","article-title":"Staging laparotomy in early ovarian cancer","volume":"250","author":"Young","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.omto.2022.08.005_bib4","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer."},{"key":"10.1016\/j.omto.2022.08.005_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1148\/radiol.2203010070","article-title":"Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care","volume":"221","author":"Spencer","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.omto.2022.08.005_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrclinonc.2010.155","article-title":"Clinical utility of image-guided peritoneal and omental biopsy","volume":"7","author":"Spencer","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib7","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1073\/pnas.0801615105","article-title":"Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2022.08.005_bib8","series-title":"Screening for Ovarian Cancer: Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement","author":"Barton","year":"2012"},{"key":"10.1016\/j.omto.2022.08.005_bib9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/gyno.2000.6071","article-title":"Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis","volume":"80","author":"Paley","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.omto.2022.08.005_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas","volume":"39","author":"Gilks","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.omto.2022.08.005_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000352","article-title":"Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series","volume":"39","author":"Morrison","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.omto.2022.08.005_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omto.2022.08.005_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","article-title":"Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis","volume":"24","author":"Yemelyanova","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.omto.2022.08.005_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1309\/AJCPU0FION3RKKFO","article-title":"Value of PAX8 and WT1 immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens","volume":"137","author":"Zhao","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.omto.2022.08.005_bib16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.omto.2022.08.005_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.omto.2022.08.005_bib18","unstructured":"12-398 Association for Molecular Pathology v. Myriad Genetics, Inc. (06\/13\/2013) (2013). 22."},{"key":"10.1016\/j.omto.2022.08.005_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive Services Task Force recommendation statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.omto.2022.08.005_bib20","series-title":"FDA Authorizes, with Special Controls, Direct-To-Consumer Test that Reports Three Mutations in the BRCA Breast Cancer Genes","author":"Commissioner","year":"2020"},{"key":"10.1016\/j.omto.2022.08.005_bib21","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.omto.2022.08.005_bib22","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/cncr.28183","article-title":"A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value","volume":"119","author":"Lu","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2022.08.005_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2022.08.005_bib25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/pon.1151","article-title":"Changes in cancer worry associated with participation in ovarian cancer screening","volume":"16","author":"Andersen","year":"2007","journal-title":"Psychooncology."},{"key":"10.1016\/j.omto.2022.08.005_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2017.21421","article-title":"Screening for ovarian cancer: updated evidence report and systematic review for the US preventive Services Task Force","volume":"319","author":"Henderson","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.omto.2022.08.005_bib27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jama.2017.21926","article-title":"Screening for ovarian cancer: US preventive Services Task Force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.omto.2022.08.005_bib28","doi-asserted-by":"crossref","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","article-title":"Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis","volume":"309","author":"Yeung","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.omto.2022.08.005_bib29","first-page":"3363","article-title":"The added value of circulating tumor cells examination in ovarian cancer staging","volume":"5","author":"Kolostova","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib30","first-page":"973","article-title":"Molecular characterization of circulating tumor cells in ovarian cancer","volume":"6","author":"Kolostova","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib31","doi-asserted-by":"crossref","first-page":"77195","DOI":"10.18632\/oncotarget.20428","article-title":"Circulating tumor cells in the differential diagnosis of adnexal masses","volume":"8","author":"Suh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.08.005_bib32","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000492521","article-title":"Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker","volume":"48","author":"Zhang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.omto.2022.08.005_bib33","doi-asserted-by":"crossref","first-page":"e15354","DOI":"10.1097\/MD.0000000000015354","article-title":"Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: a prospective observational study","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.omto.2022.08.005_bib34","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/1947601910396213","article-title":"MicroRNA in cancer: the involvement of aberrant MicroRNA biogenesis regulatory pathways","volume":"1","author":"Davis-Dusenbery","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138920210793175895","article-title":"MicroRNA: biogenesis, function and role in cancer","volume":"11","author":"Macfarlane","year":"2010","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.omto.2022.08.005_bib36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/1471-2407-12-627","article-title":"Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer","volume":"12","author":"Kan","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","article-title":"Clinical relevance of circulating cell-free microRNAs in ovarian cancer","volume":"15","author":"Nakamura","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/22115374OTY4aMzknTcVY","article-title":"The promising signatures of circulating microRNA-145 in epithelial ovarian cancer patients","volume":"9","author":"Zuberi","year":"2020","journal-title":"Microrna"},{"key":"10.1016\/j.omto.2022.08.005_bib39","article-title":"Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations","volume":"3","author":"Hu","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI81135","article-title":"The biology and function of exosomes in cancer","volume":"126","author":"Kalluri","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2022.08.005_bib41","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omto.2022.08.005_bib42","doi-asserted-by":"crossref","first-page":"21493","DOI":"10.1002\/jcp.28905","article-title":"The potential role of exosomes derived from ovarian cancer cells for diagnostic and therapeutic approaches","volume":"234","author":"Yang","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omto.2022.08.005_bib43","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.omto.2022.08.005_bib44","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.3390\/cancers12123563","article-title":"Emerging role of extracellular vesicles in immune regulation and cancer progression","volume":"12","author":"Mittal","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omto.2022.08.005_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-4939-9773-2_8","article-title":"Techniques associated with exosome isolation for biomarker development: liquid biopsies for ovarian cancer detection","volume":"2055","author":"Sharma","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omto.2022.08.005_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles","volume":"30","author":"Colombo","year":"2014","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.omto.2022.08.005_bib47","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jprot.2010.06.006","article-title":"Exosomes: extracellular organelles important in intercellular communication","volume":"73","author":"Mathivanan","year":"2010","journal-title":"J.\u00a0Proteomics"},{"key":"10.1016\/j.omto.2022.08.005_bib48","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/jth.12602","article-title":"Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing","volume":"12","author":"van der Pol","year":"2014","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.omto.2022.08.005_bib49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.colsurfb.2011.05.013","article-title":"Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy","volume":"87","author":"Sokolova","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.omto.2022.08.005_bib50","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/1055-9965.EPI-16-0006","article-title":"Circulating long RNAs in serum extracellular vesicles: their characterization and potential application as biomarkers for diagnosis of colorectal cancer","volume":"25","author":"Dong","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.omto.2022.08.005_bib51","first-page":"Unit.3.22","article-title":"Isolation and characterization of exosomes from cell culture supernatants and biological fluids","volume":"Chapter 3","author":"Th\u00e9ry","year":"2006","journal-title":"Curr. Protoc. Cell Biol."},{"key":"10.1016\/j.omto.2022.08.005_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/cancers14010158","article-title":"Understanding the role and clinical applications of exosomes in gynecologic malignancies: a review of the current literature","volume":"14","author":"Roy","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omto.2022.08.005_bib53","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3892\/ijmm.2017.3080","article-title":"Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum","volume":"40","author":"Tang","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.omto.2022.08.005_bib54","doi-asserted-by":"crossref","first-page":"20360","DOI":"10.3402\/jev.v2i0.20360","article-title":"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research","volume":"2","author":"Witwer","year":"2013","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.omto.2022.08.005_bib55","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/cr.2014.44","article-title":"Double-stranded DNA in exosomes: a novel biomarker in cancer detection","volume":"24","author":"Thakur","year":"2014","journal-title":"Cell Res."},{"key":"10.1016\/j.omto.2022.08.005_bib56","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/0008-5472.CAN-18-3538","article-title":"A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer","volume":"79","author":"Dorayappan","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41551-019-0356-9","article-title":"Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip","volume":"3","author":"Zhang","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omto.2022.08.005_bib58","first-page":"003","article-title":"Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy","volume":"4","author":"Szajnik","year":"2013","journal-title":"Gynecol. Obstet."},{"key":"10.1016\/j.omto.2022.08.005_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2008.04.033","article-title":"MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer","volume":"110","author":"Taylor","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib60","doi-asserted-by":"crossref","first-page":"9149","DOI":"10.1038\/s41598-021-88163-1","article-title":"Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells","volume":"11","author":"Mitra","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2022.08.005_bib61","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2007.08.064","article-title":"Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM","volume":"107","author":"Runz","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/1471-2407-9-244","article-title":"Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer","volume":"9","author":"Li","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jprot.2012.12.029","article-title":"Characterization and proteomic analysis of ovarian cancer-derived exosomes","volume":"80","author":"Liang","year":"2013","journal-title":"J.\u00a0Proteomics"},{"key":"10.1016\/j.omto.2022.08.005_bib64","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1002\/jcb.27923","article-title":"Detection of exosomal tyrosine receptor kinase B as a potential biomarker in ovarian cancer","volume":"120","author":"Li","year":"2019","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.omto.2022.08.005_bib65","doi-asserted-by":"crossref","first-page":"e2104452","DOI":"10.1002\/advs.202104452","article-title":"Tumor derived extracellular vesicles drive T\u00a0cell exhaustion in tumor microenvironment through sphingosine mediated signaling and impacting immunotherapy outcomes in ovarian cancer","volume":"9","author":"Gupta","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omto.2022.08.005_bib66","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/biom5031741","article-title":"Extracellular vesicles from ovarian carcinoma cells display specific glycosignatures","volume":"5","author":"Gomes","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.omto.2022.08.005_bib67","doi-asserted-by":"crossref","first-page":"e78631","DOI":"10.1371\/journal.pone.0078631","article-title":"Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells","volume":"8","author":"Escrevente","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2022.08.005_bib68","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/s12885-018-4974-5","article-title":"Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells","volume":"18","author":"Yoshimura","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib69","doi-asserted-by":"crossref","first-page":"16923","DOI":"10.18632\/oncotarget.7850","article-title":"Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer","volume":"7","author":"Meng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.08.005_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1479-5876-12-4","article-title":"Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200","volume":"12","author":"Kobayashi","year":"2014","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omto.2022.08.005_bib71","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncy.21442","article-title":"Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions","volume":"122","author":"Cappellesso","year":"2014","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.omto.2022.08.005_bib72","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3892\/or.2015.3937","article-title":"Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma","volume":"33","author":"Zhou","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2022.08.005_bib73","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/2211-5463.12257","article-title":"MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor","volume":"7","author":"Xu","year":"2017","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.omto.2022.08.005_bib74","doi-asserted-by":"crossref","first-page":"89811","DOI":"10.18632\/oncotarget.20688","article-title":"A combination of circulating miRNAs for the early detection of ovarian cancer","volume":"8","author":"Yokoi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.08.005_bib75","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/1878-0261.12371","article-title":"Exosomal microRNAs as tumor markers in epithelial ovarian cancer","volume":"12","author":"Pan","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13048-018-0458-0","article-title":"Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types","volume":"11","author":"Kobayashi","year":"2018","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.omto.2022.08.005_bib77","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-16-0714","article-title":"Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells","volume":"76","author":"Kanlikilicer","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13048-018-0477-x","article-title":"Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer","volume":"12","author":"Su","year":"2019","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.omto.2022.08.005_bib79","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/carcin\/bgu130","article-title":"Exosome-derived miRNAs and ovarian carcinoma progression","volume":"35","author":"Vaksman","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.omto.2022.08.005_bib80","doi-asserted-by":"crossref","first-page":"20145","DOI":"10.18632\/oncotarget.15525","article-title":"Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs","volume":"8","author":"Rashed","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.08.005_bib81","doi-asserted-by":"crossref","first-page":"43076","DOI":"10.18632\/oncotarget.9246","article-title":"Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages","volume":"7","author":"Ying","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.08.005_bib82","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.7150\/jca.30231","article-title":"Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas","volume":"10","author":"Kim","year":"2019","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib83","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12935-019-0990-z","article-title":"Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omto.2022.08.005_bib84","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13048-021-00826-9","article-title":"MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer","volume":"14","author":"Xiong","year":"2021","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.omto.2022.08.005_bib85","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s13577-021-00522-2","article-title":"Exosomal miR-21-5p contributes to ovarian cancer progression by regulating CDK6","volume":"34","author":"Cao","year":"2021","journal-title":"Hum. Cell"},{"key":"10.1016\/j.omto.2022.08.005_bib86","doi-asserted-by":"crossref","first-page":"652322","DOI":"10.3389\/fcell.2021.652322","article-title":"Tumor-derived extracellular vesicles promote activation of carcinoma-associated fibroblasts and facilitate invasion and metastasis of ovarian cancer by carrying miR-630","volume":"9","author":"Cui","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omto.2022.08.005_bib87","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2018.01.004","article-title":"Expression and clinical role of long non-coding RNA in high-grade serous carcinoma","volume":"148","author":"Filippov-Levy","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13046-021-01899-6","article-title":"LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1","volume":"40","author":"Wang","year":"2021","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib89","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.7150\/ijbs.28048","article-title":"Exosomal metastasis-associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer","volume":"14","author":"Qiu","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omto.2022.08.005_bib90","doi-asserted-by":"crossref","first-page":"23726","DOI":"10.18632\/aging.203645","article-title":"Exosome long non-coding RNA SOX2-OT contributes to ovarian cancer malignant progression by miR-181b-5p\/SCD1 signaling","volume":"13","author":"Lai","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.omto.2022.08.005_bib91","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ygyno.2019.03.099","article-title":"SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma","volume":"153","author":"Sherman-Samis","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib92","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13048-018-0391-2","article-title":"Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers","volume":"11","author":"Yamamoto","year":"2018","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.omto.2022.08.005_bib93","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jbiotec.2019.04.015","article-title":"Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer","volume":"298","author":"Keser\u0171","year":"2019","journal-title":"J.\u00a0Biotechnol."},{"key":"10.1016\/j.omto.2022.08.005_bib94","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0002-9440(10)64398-2","article-title":"CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival","volume":"161","author":"Kristiansen","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omto.2022.08.005_bib95","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/cells9081836","article-title":"Epithelial cell adhesion molecule: an anchor to isolate clinically relevant circulating tumor cells","volume":"9","author":"Eslami-S","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omto.2022.08.005_bib96","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/sj.bjc.6603023","article-title":"MicroRNAs in cell proliferation, cell death, and tumorigenesis","volume":"94","author":"Hwang","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib97","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2021.02.004","article-title":"Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers","volume":"161","author":"Hashemipour","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib98","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tcb.2011.12.001","article-title":"Secreted microRNAs: a new form of intercellular communication","volume":"22","author":"Chen","year":"2012","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omto.2022.08.005_bib99","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/0008-5472.CAN-07-1936","article-title":"MicroRNA signatures in human ovarian cancer","volume":"67","author":"Iorio","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib100","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.celrep.2016.04.034","article-title":"Direct upregulation of STAT3 by MicroRNA-551b-3p deregulates growth and metastasis of ovarian cancer","volume":"15","author":"Chaluvally-Raghavan","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.omto.2022.08.005_bib101","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ccell.2014.10.010","article-title":"Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers","volume":"26","author":"Chaluvally-Raghavan","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2022.08.005_bib102","doi-asserted-by":"crossref","first-page":"E1015","DOI":"10.3390\/cells8091015","article-title":"Long non-coding RNA in the pathogenesis of cancers","volume":"8","author":"Chi","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.omto.2022.08.005_bib103","first-page":"5143","article-title":"Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer","volume":"20","author":"Zhang","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.omto.2022.08.005_bib104","doi-asserted-by":"crossref","first-page":"e0114586","DOI":"10.1371\/journal.pone.0114586","article-title":"The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2022.08.005_bib105","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1021\/acssensors.0c00953","article-title":"Hybrid nanoplasmonic porous biomaterial scaffold for liquid biopsy diagnostics using extracellular vesicles","volume":"5","author":"Rojalin","year":"2020","journal-title":"ACS Sens."},{"key":"10.1016\/j.omto.2022.08.005_bib106","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1039\/C5NR01333J","article-title":"3D plasmonic nanobowl platform for the study of exosomes in solution","volume":"7","author":"Lee","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.omto.2022.08.005_bib107","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/jrs.5234","article-title":"SERS analysis of selectively captured exosomes using an integrin-specific peptide ligand","volume":"48","author":"Lee","year":"2017","journal-title":"J.\u00a0Raman Spectrosc."},{"key":"10.1016\/j.omto.2022.08.005_bib108","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1039\/D1AN01586A","article-title":"Characterization of ovarian cancer-derived extracellular vesicles by surface-enhanced Raman spectroscopy","volume":"146","author":"\u0106ulum","year":"2021","journal-title":"Analyst"},{"key":"10.1016\/j.omto.2022.08.005_bib109","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/1541-7786.MCR-20-0956","article-title":"Exosomal CD47 plays an essential role in immune evasion in ovarian cancer","volume":"19","author":"Shimizu","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib110","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.omtn.2021.05.011","article-title":"TAM-derived extracellular vesicles containing microRNA-29a-3p explain the deterioration of ovarian cancer","volume":"25","author":"Lu","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omto.2022.08.005_bib111","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.2147\/CMAR.S210568","article-title":"Malignant ascite-derived extracellular vesicles inhibit T\u00a0cell activity by upregulating Siglec-10 expression","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.omto.2022.08.005_bib112","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","article-title":"Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma","volume":"10","author":"Czystowska-Kuzmicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2022.08.005_bib113","doi-asserted-by":"crossref","first-page":"e1655370","DOI":"10.1080\/2162402X.2019.1655370","article-title":"Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response","volume":"8","author":"Sosnowska","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omto.2022.08.005_bib114","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","article-title":"Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells","volume":"15","author":"Nakamura","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.omto.2022.08.005_bib115","doi-asserted-by":"crossref","first-page":"14470","DOI":"10.1038\/ncomms14470","article-title":"Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer","volume":"8","author":"Yokoi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2022.08.005_bib116","first-page":"722","article-title":"Ovarian cancer-derived extracellular vesicles affect normal human fibroblast behavior","volume":"19","author":"Giusti","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.omto.2022.08.005_bib117","doi-asserted-by":"crossref","first-page":"102207","DOI":"10.1016\/j.nano.2020.102207","article-title":"miRNa signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer","volume":"28","author":"Alharbi","year":"2020","journal-title":"Nanomedicine."},{"key":"10.1016\/j.omto.2022.08.005_bib118","doi-asserted-by":"crossref","first-page":"R663","DOI":"10.1530\/ERC-18-0019","article-title":"The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer","volume":"25","author":"Alharbi","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib119","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/cancers13143388","article-title":"Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrence","volume":"13","author":"Alharbi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2022.08.005_bib120","first-page":"100364","article-title":"Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells","volume":"27","author":"Misawa","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.omto.2022.08.005_bib121","doi-asserted-by":"crossref","first-page":"20170065","DOI":"10.1098\/rstb.2017.0065","article-title":"Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells","volume":"373","author":"Samuel","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.omto.2022.08.005_bib122","series-title":"FDA Grants Accelerated Approval to Pembrolizumab for First Tissue\/site Agnostic Indication","author":"Research","year":"2019"},{"key":"10.1016\/j.omto.2022.08.005_bib123","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2022.08.005_bib124","doi-asserted-by":"crossref","first-page":"553576","DOI":"10.3389\/fcell.2020.553576","article-title":"Immune (cell) derived exosome mimetics (IDEM) as a treatment for ovarian cancer","volume":"8","author":"Pisano","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omto.2022.08.005_bib125","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.3390\/cancers13123075","article-title":"Engineered EV-mimetic nanoparticles as therapeutic delivery vehicles for high-grade serous ovarian cancer","volume":"13","author":"Al-Dossary","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omto.2022.08.005_bib126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s42003-021-02004-5","article-title":"ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance","volume":"4","author":"Jang","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omto.2022.08.005_bib127","doi-asserted-by":"crossref","first-page":"E1185","DOI":"10.3390\/jcm9041185","article-title":"Photodynamic therapy using a new folate receptor-targeted photosensitizer on peritoneal ovarian cancer cells induces the release of extracellular vesicles with immunoactivating properties","volume":"9","author":"Baydoun","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omto.2022.08.005_bib128","doi-asserted-by":"crossref","first-page":"e23369","DOI":"10.1002\/dvg.23369","article-title":"Reporter mice for isolating and auditing cell type-specific extracellular vesicles in\u00a0vivo","volume":"58","author":"McCann","year":"2020","journal-title":"Genesis"},{"key":"10.1016\/j.omto.2022.08.005_bib129","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.3390\/cells7080093","article-title":"The role of extracellular vesicles in cancer: cargo, function, and therapeutic implications","volume":"7","author":"Jabalee","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.omto.2022.08.005_bib130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omto.2022.08.005_bib131","doi-asserted-by":"crossref","first-page":"114001","DOI":"10.1016\/j.addr.2021.114001","article-title":"Development of extracellular vesicle-based medicinal products: a position paper of the group \u201cExtracellular Vesicle translatiOn to clinicaL perspectiVEs \u2013 EVOLVE France","volume":"179","author":"Silva","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omto.2022.08.005_bib132","series-title":"Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue (clinicaltrials.gov)","author":"Dryden","year":"2021"},{"key":"10.1016\/j.omto.2022.08.005_bib133","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbcan.2017.10.001","article-title":"Extracellular vesicles as emerging targets in cancer: recent development from bench to bedside","volume":"1868","author":"Wu","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.omto.2022.08.005_bib134","series-title":"Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes with KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation (clinicaltrials.gov)","author":"Anderson Cancer Center","year":"2022"},{"key":"10.1016\/j.omto.2022.08.005_bib135","doi-asserted-by":"crossref","first-page":"677541","DOI":"10.3389\/fbioe.2021.677541","article-title":"Autologous platelet- and extracellular vesicle-rich plasma is an effective treatment modality for chronic postoperative temporal bone cavity inflammation: randomized controlled clinical trial","volume":"9","author":"Vozel","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omto.2022.08.005_bib136","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41587-019-0326-5","article-title":"Exosome redux","volume":"37","author":"Zipkin","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omto.2022.08.005_bib137","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/d41573-020-00220-y","article-title":"Exosome-based candidates move into the clinic","volume":"20","author":"Cully","year":"2020","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:24:25Z","timestamp":1762496665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770522001048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":136,"alternative-id":["S2372770522001048"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2022.08.005","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}